MaxCyte’s flow electroporation is driving the next generation of cell-based medicines. Used in the discovery, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.
MicroBiopharm Japan has been manufacturing high-potent compounds by fermentation technique for a long time. These natural compounds and their derivatives are used as anticancer drugs usually. In addition, they could also be used as payloads in the field of ADC such as DM-1 (Ansamitocin P3 derivative), Doxorubicin, Alpha-amanitin, Camptotecin analogues, and so on. MicroBiopharm Japan supports development of ADC drugs by supply of these payloads and their linker conjugates at a competitive price and high quality.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery.
Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation… Read More
Morphotek® is a biotechnology company focused on the development of antibody-based therapies. In oncology, we are developing biological therapies that target underlying disease pathways and can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. As part of this approach, we have developed proprietary ADC technologies that utilize REsidue-SPEcific Conjugation Technology™ (RESPECT™) and proprietary payloads to develop ADCs to internal and clients’ strategic targets through our end-to-end ADC Services
NOF Corporation is the leading commercial supplier of activated PEG products and is providing site-specific linkers, such as, linear and branched hetero-activated PEG, and single molecular weight PEGs for the development of next generation Antibody-Drug Conjugates. NOF also supplies ultra-pure polysorbates 20 and 80 for stabilizing the formulation of antibody and protein… Read More.
Pierre FABRE CDMO proposes its international partners a full service, from clinical development to commercial production in the following fields of expertises: manufacturing of APIs, supercritical CO2 formulation, production of pharmaceutical lozenges and fill & finish of injectable products (vials, prefilled syringes), including conventional cytotoxic and biotechnology products… Read More.
Recipharm is a leading CDMO with 3,500 employees, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm operates facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Sweden. Recipharm has extensive experience in medicinal chemistry including specialities such as ADC offerings, radiolabelling and non-GMP scale up chemistry.
Quanta BioDesign was founded for the purpose of developing a line of products involved in drug discovery and diagnostic development. For 30 years the PEGylation of biologics has been completely defined by the use of generally high MW and highly polydispersed PEGs. While showing promising results in the clinic, it has serious limitations in control and characterization. Our single molecular weight ethylene glycol conjugation technology, dPEG, can eliminate common problems found in the development of diagnostic and therapeutic products.